

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	O		ARM	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	
			R	P			LAST	LAST	LAST	LAST	LAST	
			E	E				Month	Month	Month	DAYS	DAYS
			G	N				12	6	3	30	7
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac	PREV		0	Y	0	Pre-Registration	621	28	17	8	2	1
			621	28	17	8	2	1				
			1	Y	1	Blinded drug	111	17	11	6	2	0
			2	Blinded drug	36	0	0	0	0	0		
			3	Blinded drug	35	0	0	0	0	0		
			4	Blinded drug	114	19	10	6	1	0		
							296	36	21	12	3	0
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	BREAST	SXQOL	1	Y	1	Tissue for PD-L1 testing	1118	379	200	99	35	4
			1118	379	200	99	35	4				
			2	Y	2	Observation	479	160	86	40	16	6
			3	MK-3475 (Pembrolizumab)	475	162	83	36	8	1		
							954	322	169	76	24	7
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol	SURV		1	Y	0	Screening	231	68	30	11	2	0
			231	68	30	11	2	0				
			2	Y	1	Carvedilol	42	12	3	2	1	0
			2	No prophylaxis	44	13	7	1	0	0		
			3	Observation	131	37	17	8	2	0		
							217	62	27	11	3	0
S1600-Bladder,Radical Cystectomy Outcomes Nutrition	SXQOL		1	Y	1	Blinded Nutrition Drink	7	2	2	2	2	2
			2	Blinded Nutrition Drink	11	1	1	1	1	1		
							18	3	3	3	3	3
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	GU	SXQOL	1	Y	1	TICE BCG	318	150	79	44	12	2
			2	Tokyo-172 BCG	322	154	82	47	15	5		
			3	Prime + Tokyo-172 BCG	327	160	87	48	18	4		
							967	464	248	139	45	11
S1614-HBV in Ca Pts, TAF vs SOC	SXQOL		1	T	4	SOC HBV Treatment	2	2	0	0	0	0
							2	2	0	0	0	0

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	O R P E E G N	ARM	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.		
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS		
S1703-Met Breast, STM-monitoring v Usual Care	CCD	SXQOL	1	Y 0 Screening	194	104	62	32	7	1		
					194	104	62	32	7	1		
					2	Y 1 Control (Usual Care)	55	31	20	13	3	1
					2	Intervention (STMDDM)	56	33	19	12	2	1
					111	64	39	25	5	2		
S1714-CIPN Risk Prediction Cohort Study, Taxanes	SXQOL		1	Y 1 Observation	568	466	270	171	68	11		
					568	466	270	171	68	11		
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum	GU	SXQOL	1	Y 0 Induction SST	271	132	78	42	13	1		
					271	132	78	42	13	1		
					2	Y 1 Standard Systemic Therapy Only	91	51	22	9	2	0
					2	SST + Surgery/RT	92	52	24	12	1	0
					183	103	46	21	3	0		
S1806-Blad, MIBC, ChemoRT +/- Atezolizumab	GU	SXQOL	1	Y 0 Initial Registration	116	94	42	21	6	1		
					116	94	42	21	6	1		
					2	Y 1 Chemo + RT	53	42	19	11	1	0
					2	Chemo + RT + Atezolizumab	52	45	20	9	4	0
					105	87	39	20	5	0		
S1820-Rectal, Diet modification to manage GI sx	PEOLC	SXQOL	1	Y 0 Run-In	41	41	33	12	5	0		
					41	41	33	12	5	0		
					2	Y 1 Diet Modification Coaching	14	14	14	4	0	0
					2	Healthy Living Education	12	12	10	3	0	0
					26	26	24	7	0	0		
S1823-GCT, Obs. Cohort, miRNA371	PREV		1	Y 1 Observation	32	32	32	30	14	5		
					32	32	32	30	14	5		

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	O		ARM	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.
			R	P			LAST	LAST	LAST	LAST	LAST
			E	E			12	6	3	30	7
			G	N			Month	Month	Month	DAYS	DAYS
S1826-HD, Adv, Age 12+, N+AVD vs BV+AVD	LYMPH	SXQOL	1	Y	1 Nivolumab + AVD	133	124	69	37	10	2
			2		Brentuximab Vedotin + AVD	134	121	71	39	13	2
						267	245	140	76	23	4
S1827-SCLC, MRI Surveillance +/- PCI	LUNG	SXQOL	1	Y	1 PCI + MRI brain surveillance	9	9	8	5	0	0
			2		MRI brain surveillance	10	10	9	3	0	0
						19	19	17	8	0	0
S1904-Breast, Decision making for chemoprevention	PREV		1	Y		0	0	0	0	0	0
						0	0	0	0	0	0
						0	0	0	0	0	0
A021502-Colon, Stg III, Chemo +/- Atezol, ATOMIC	GI	SXQOL	1	E		37	16	10	7	4	0
						37	16	10	7	4	0
						37	16	10	7	4	0
A031102-GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE)	GU	SXQOL	1	E		7	1	1	0	0	0
						7	1	1	0	0	0
						7	1	1	0	0	0
A031704-RCC, Met, Ipi+Nivo followed by Nivo+/-Cabo	GU	SXQOL	1	E		40	38	24	15	5	0
						40	38	24	15	5	0
						40	38	24	15	5	0
			2	E		19	19	12	6	4	2
						19	19	12	6	4	2
						19	19	12	6	4	2
A221602-CINV in HEC patients, Olanza +/- Fosapre	SXQOL	PREV	1	E		19	19	6	5	3	1
						19	19	6	5	3	1
						19	19	6	5	3	1
			2	E		10	10	3	2	1	0
						10	10	3	2	1	0
						10	10	3	2	1	0
EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	MELAN	SXQOL	1	E		49	5	1	0	0	0
						49	5	1	0	0	0
						49	5	1	0	0	0
			2	E		19	5	3	2	1	0
						19	5	3	2	1	0
						19	5	3	2	1	0

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	O R P E E G N	ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.	
					REGS.	LAST	LAST	LAST	LAST	LAST	
					REGS.	Month	Month	Month	DAYS	DAYS	
EA8143-RCC, HR, Surg +/- Nivolumab (PROSPER)	GU	SXQOL	0	E		137	58	29	11	4	1
						137	58	29	11	4	1
					1	125	54	27	11	6	0
						125	54	27	11	6	0
EA9161-CLL, untreated, IOV vs IO in younger pts	LEUK	SXQOL	0	E		89	71	37	18	8	2
						89	71	37	18	8	2
					1	135	71	36	17	9	2
						135	71	36	17	9	2
MA39-BREAST, Node-Pos, Reg RT vs No Reg RT	BREAST	SXQOL	1	E		2	1	0	0	0	0
						2	1	0	0	0	0
					2	2	1	0	0	0	0
						2	1	0	0	0	0
NRGBR004-BREAST, Met HER2+, Pac+Tras+Pert +/- Atezo	BREAST	SXQOL	1	E		6	5	3	2	1	0
						6	5	3	2	1	0
					2	3	2	1	1	0	0
						3	2	1	1	0	0
NRGCC003-SCLC, PCI or HA-PCI	LUNG	SXQOL	1	E		4	0	0	0	0	0
						4	0	0	0	0	0
					2	4	0	0	0	0	0
						4	0	0	0	0	0
NRGGU005-PROS, intrmd risk, IGRT& SBRT vs IGRT& HF-IMRT	GU	SXQOL	1	E		5	4	4	3	2	0
						5	4	4	3	2	0
NRGLU002-LUNG, Limited Met NSCLC, MST vs LCT + MST	LUNG	SXQOL	1	E		1	0	0	0	0	0

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	G	N	ARM	O R P E E	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.
							REGS.	LAST	LAST	LAST	LAST	LAST
							Month	Month	Month	Month	Month	Month
							DAYS	DAYS	DAYS	DAYS	DAYS	DAYS
							1	0	0	0	0	0
A011401-Breast, adj, Stage II/III HER2-, weight loss	BREAST	SXQOL	1	E			320	41	17	8	3	1
							320	41	17	8	3	1
			2	E			298	38	16	8	3	1
							298	38	16	8	3	1
			3	E			1	1	1	1	1	1
							1	1	1	1	1	1
A011502-Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo	BREAST	PREV	1	E			202	62	39	22	8	3
							202	62	39	22	8	3
A021602-PANC, Adv PNET Blinded Cabozantinib v Placebo	GI	SXQOL	1	E			10	5	3	2	2	0
							10	5	3	2	2	0
A021806-Pancreas, Perioperative vs Adjuvant Chemo	GI	SXQOL	0	E			1	1	1	1	0	0
							1	1	1	1	0	0
			1	E			1	1	1	1	0	0
							1	1	1	1	0	0
A031501-Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs	GU	SXQOL	0	E			88	31	22	9	3	1
							88	31	22	9	3	1
			1	E			80	25	18	6	2	0
							80	25	18	6	2	0
A031801-GU, mRCC, Cabozantinib +/- Radium-223	GU	SXQOL	1	E			1	1	1	1	1	0
							1	1	1	1	1	0
A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO	LUNG	SXQOL	1	E			4	4	4	4	1	0
							4	4	4	4	1	0

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	O R P E E G N	ARM	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS
A211102-Breast, Atypia via RPFNA, Metformin v Placebo	PREV		0	E	6	0	0	0	0	0
			6	0	0	0	0	0		
			1	E	3	0	0	0	0	0
			3	0	0	0	0	0		
A211601-Breast, Stg II-III, Aspirin	PREV		1	E	2	0	0	0	0	0
			2	0	0	0	0	0		
			1	E	20	0	0	0	0	0
			20	0	0	0	0	0		
A221505-Brst, Hypofractionated Post Mast Rad	SXQOL		1	E	20	6	3	0	0	0
			20	6	3	0	0	0		
			1	E	15	15	0	0	0	0
			15	15	0	0	0	0		
A221805-Colorectal, Duloxetine for Oxaliplatin CIPN	SXQOL		1	E	1	1	1	1	0	0
			1	1	1	1	0	0		
			1	E	4	4	4	0	0	0
			4	4	4	0	0	0		
A231602C-Blood Cancer, Assess Financial Difficulty	CCD		1	E	1	1	0	0	0	0
			1	1	0	0	0	0		
			1	E	1	1	0	0	0	0
			1	1	0	0	0	0		
AGCT1532-Inter/Poor Met GCTs, Accel v Std BEP Chemo	OTHER	SXQOL	1	E	47	8	5	2	1	0
			47	8	5	2	1	0		
			1	E	2	2	2	2	2	0
			2	2	2	2	2	0		

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	O		ARM	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	
			R	P			LAST	LAST	LAST	LAST	LAST	
			E	E				12	6	3	30	7
			G	N				Month	Month	Month	DAYS	DAYS
						2	2	2	2	2	2	0
EA8134-Penile, Local Adv, ILND +/- Chemo or ChemoRT	GU	SXQOL	1	E		6	2	0	0	0	0	0
						6	2	0	0	0	0	0
EA9131-Leuk, Strategy to decrease early APL deaths	SURV		1	E		51	16	12	7	2	0	0
						51	16	12	7	2	0	0
EAA173-MYEL, SMM, Rd +/- Daratumumab	MMYEL	SXQOL	0	E		21	21	12	4	3	0	0
						21	21	12	4	3	0	0
			1	E		9	9	4	1	0	0	0
						9	9	4	1	0	0	0
EAQ171CD-Smoke Free Support Study 2.0	CCD		0	E		1	0	0	0	0	0	0
						1	0	0	0	0	0	0
			1	E		1	0	0	0	0	0	0
						1	0	0	0	0	0	0
EAZ171-Breast, Stg I-III, TIPN Docetaxel/Paclitaxel	SXQOL		1	E		1	1	1	0	0	0	0
						1	1	1	0	0	0	0
G0263-Cerv, Stg I/IIA, adjv RT vs chemoRT	OTHER	SXQOL	1	E		1	0	0	0	0	0	0
						1	0	0	0	0	0	0
NHLBIMDS-LEUK, National MDS Study	CCD		1	E		94	31	18	13	7	1	1
						94	31	18	13	7	1	1
NRGBN003-Mening, Grd II, Observation vs Irradiation	OTHER	SXQOL	1	E		5	2	0	0	0	0	0
						5	2	0	0	0	0	0
			2	E		3	2	0	0	0	0	0
						3	2	0	0	0	0	0

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	O R P E E G N	ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.
					REGS.	LAST	LAST	LAST	LAST	LAST
					12	6	3	30	7	
					Month	Month	Month	DAYS	DAYS	
NRGCC007-CCD, Increased Dose of SCP in Pros Survivors	CCD		0	E	2	2	2	2	1	0
					2	2	2	2	1	0
			1	E	2	2	2	2	1	0
					2	2	2	2	1	0
NRGGU008-Pros,Node+, Abiraterone acetate + Apalutamide	GU	SXQOL	1	E	1	1	1	1	0	0
					1	1	1	1	0	0
NRGGY005-OVAR, Cedir vs Olaparib vs C+O vs Std of Care	OTHER	SXQOL	1	E	4	0	0	0	0	0
					4	0	0	0	0	0
NRGHN001-Nasopharyngeal , Individual Tx EBV	OTHER	SXQOL	1	E	9	0	0	0	0	0
					9	0	0	0	0	0
			2	E	8	0	0	0	0	0
					8	0	0	0	0	0
NRGHN004-HN, Adv, RT+Durvalumab vsOTHER RT+Cetuximab		SXQOL	1	E	6	4	4	2	1	0
					6	4	4	2	1	0
			2	E	6	4	4	2	1	0
				6	4	4	2	1	0	
NRGHN005-HN, early stg P16-pos, randomize de-intensifi	OTHER	SXQOL	1	E	3	3	0	0	0	0
					3	3	0	0	0	0
NRGLU005-LUNG, LS-SCLC, ChemoRT LUNG v ChemoRT+Atezo		SXQOL	1	E	1	0	0	0	0	0
					1	0	0	0	0	0
R0724-Cervical, Chem+RT +/- Adj. Chemo	OTHER	SXQOL	1	E	1	0	0	0	0	0

CANCER CONTROL ACCRUAL REPORT

Accrual to Studies with Any Cancer Control Committee as the Primary or CC Committee

STUDY	ADMIN	CCADMIN	O R P E E G N ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.
				REGS.	LAST	LAST	LAST	LAST	LAST
				Month	Month	Month	Month	Month	Month
				DAYS	DAYS	DAYS	DAYS	DAYS	DAYS
				1	0	0	0	0	0

Cancer Control Open Studies with No Registrations

<u>Study</u>	<u>Admin</u>	<u>CCAdmin</u>	<u>Registration/Phase</u>	<u>Open Date</u>
S1904 Breast, Decision making for chemoprevention	PREV		1 Registration	01-Sep-20